Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016

  • ID: 3788891
  • Report
  • 60 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Complix NV
  • Princeton University
  • MORE
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016

Summary

‘Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016’, provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted pipeline therapeutics.

The report provides comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1)
- The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Complix NV
  • Princeton University
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Overview

Therapeutics Development

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Stage of Development

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Therapy Area

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Indication

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Companies

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Universities/Institutes

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Companies Involved in Therapeutics Development

AbbVie Inc.

Complix NV

Les Laboratoires Servier SAS

Princeton University

Takeda Pharmaceutical Company Limited

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Drug Profiles

AT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins to Inhibit MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Mcl-1 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMI-77 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Dormant Projects

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Featured News & Press Releases

Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies

Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer

Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent

Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent

Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent

Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent

Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting

Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting

Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting

May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting

May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting

Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer

Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer

Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia

Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 60List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AbbVie Inc., H1 2016

Pipeline by Complix NV, H1 2016

Pipeline by Les Laboratoires Servier SAS, H1 2016

Pipeline by Princeton University, H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016 45List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Complix NV
  • Princeton University
  • MORE
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 – Pipeline Review, H1 2016, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc.
Complix NV
Les Laboratoires Servier SAS
Princeton University
Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll